Home > Opioid Receptor & Opioid Receptor & Opioid Receptor  & > Naltrexone HCl

Naltrexone HCl

盐酸纳曲酮

Naltrexone Hydrochloride (盐酸纳曲酮) 是阿片受体拮抗剂。

目录号
EY1576
EY1576
纯度
99.45%
99.45%
规格
50 mg
100 mg
原价
500
700
售价
500
700
库存
现货
现货
订购
订购
订购
订购
订购
订购
具体折扣请咨询客服

  • 生物活性

    Naltrexone hydrochlorideis an opioid receptor antagonist used primarily in the management of alcohol dependence and opioid dependence.

  • 体外研究

  • 体内研究

  • 激酶实验

  • 细胞实验

  • 动物实验

  • 不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）

    动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数


    例如，已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法：将88 mg/kg 乘以小鼠的Km系数（3），再除以大鼠的Km系数（6），得到该药物用于大鼠的等效剂量44 mg/kg。

  • 参考文献

    [1] Williams KL, et al. Psychopharmacology (Berl), 1998, 139(1-2), 53-61.
    [2] Tempel et al (1982) Supersensitivity of brain opiate receptor subtypes after chronic naltrexone treatment. Life Sci. 31 1401.
    [3] Gold et al (1982) Naltrexone, opiate addiction, and endorphins. Med.Res.Rev. 2 211.
    [4] Zukin et al (1982) Naltrexone-induced opiate receptor supersensitivity. Brain Res. 245 285.

    分子式
    C20H24ClNO4    		 分子量
    377.86    		 CAS号
    16676-29-2    		 储存方式
    ﹣20 ℃冷藏长期储存。冰袋运输
    溶剂（常温）
    		 DMSO
    10 mg/mL    		 Water
    10 mg/mL    		 Ethanol
    <1 mg/mL

    体内溶解度

  • Clinical Trial Information ( data from http://clinicaltrials.gov )

    NCT Number Conditions Interventions Sponsor/Collaborators Phases Start Date Last Updated
    NCT02616315 Weight Regain Post Bariatric Surgery Drug: Naltrexone HCl/Bupropion HCl Placebo|Drug: Naltrexone HCl/Bupropion HCl Takeda Phase 4 2016-02-01 2016-04-07
    NCT02965768 Fatigue Syndrome, Chronic Drug: Naltrexone HCl University of Alabama at Birmingham 2016-01-01 2017-03-20
    NCT01053078 Type 1 Diabetes|Hypoglycemia Unawareness Drug: Naltrexone|Drug: Naltrexone University of Minnesota - Clinical and Translational Science Institute|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|American Diabetes Association Phase 1|Phase 2 2009-10-01 2016-06-23
    NCT00663117 Inflammation|Crohn's Disease Drug: Naltrexone-HCl|Drug: Placebo Penn State University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|The Broad Foundation Phase 2 2006-09-01 2013-05-16
    NCT01428583 Chronic Noncancer Pain Drug: oxycodone HCl and naltrexone HCl extended-release capsules Pfizer Phase 3 2010-12-01 2016-09-28
    NCT00577408 Opiate Dependence|Heroin Dependence Drug: depot naltrexone|Drug: Oral Naltrexone New York State Psychiatric Institute|National Institute on Drug Abuse (NIDA) Phase 3 2007-09-01 2012-10-16
    NCT02088177 Cannabis Dependence Drug: Long-acting injectable naltrexone New York State Psychiatric Institute Phase 1|Phase 2 2014-10-01 2016-05-17
    NCT00270231 Tobacco Dependence Drug: Naltrexone|Drug: Placebo University of Pennsylvania|National Institute on Drug Abuse (NIDA) Phase 2 2004-03-01 2013-11-12
    NCT01303835 Malignant Glioma Drug: LDN|Drug: Placebo Katy Peters|Duke University Phase 2 2011-05-01 2015-06-25
    NCT01560013 Alcohol-dependence Drug: Naltrexone Tel-Aviv Sourasky Medical Center|Ministry of Health, Israel 2012-10-01 2012-03-20
    NCT00620750 Alcohol Dependence Drug: Extended release injectable naltrexone (Vivitrol) New York University School of Medicine|Alkermes, Inc. Phase 4 2007-07-01 2011-08-22
    NCT02446002 Healthy Drug: Lofexidine + Naltrexone US WorldMeds LLC Phase 1 2015-05-01 2016-10-31
    NCT00715117 Crohn's Disease Drug: Naltrexone|Other: Placebo, sugar pill Penn State University Phase 2 2008-07-01 2013-05-29
    NCT02978417 Opioid-Related Disorders Drug: Naltrexone for extended-release injectable suspension Duke University|Laura and John Arnold Foundation|Alkermes, Inc.|FHR (Fellowship Health Resources, Inc.)|Drug Treatment Court (Wake County, NC) Phase 4 2017-03-01 2016-11-30
    NCT01471145 Opioid-Related Disorders|Heroin Dependence Drug: Naltrexone Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|ZonMw: The Netherlands Organisation for Health Research and Development|Alkermes, Inc. Phase 4 2013-01-01 2014-10-10
    NCT01625611 Alcohol Drinking Drug: Naltrexone Yale University Phase 1 2011-02-01 2016-08-23
    NCT02726035 Self-injurious Behavior|Self Mutilation Drug: Naltrexone|Other: Placebo Western Michigan University School of Medicine|Kalamazoo Community Foundation Phase 4 2016-09-01 2016-04-03
    NCT00476242 Opioid Dependence|Heroin Dependence Drug: Vivitrol|Drug: memantine New York State Psychiatric Institute|National Institute on Drug Abuse (NIDA) Phase 2|Phase 3 2008-06-01 2014-06-04
    NCT00000448 Alcoholism|Eating Disorder Drug: naltrexone|Drug: Placebo Yale University|National Institute on Alcohol Abuse and Alcoholism (NIAAA) Phase 4 1995-10-01 2014-05-06
    NCT00568958 Alcohol Consumption|Alcoholic Intoxication|Alcoholism|Alcohol-induced Disorders Behavioral: BASICS counseling|Drug: naltrexone|Drug: placebo naltrexone Yale University|National Institute on Alcohol Abuse and Alcoholism (NIAAA) Phase 4 2008-02-01 2014-07-22

    注：以上所有数据均来自公开文献，并不保证对所有实验均有效，数据仅供参考。

  • 相关化合物库

  • 使用AMQUAR产品发表文献后请联系我们

相关推荐

X
  • 联系人 ：
  • 收件地址 ：
  • 电话号码 ：
  • 单位名称 ：
  • 产品货号 ：
  • 产品规格 ：
  • 发票抬头以及单位税号 ：